Home Podcasts The Lancet in conversation with
The Lancet in conversation with

The Lancet in conversation with

The Lancet Group 43 Episodes Jul 31, 2026

This podcast features editors and the audio producer of The Lancet in conversation with the journal's authors. They explore the latest research and its impact on people's health, healthcare, and health policy. It is a monthly audio companion covering a wide range of medical topics, from treatments and drug trials to public health outbreaks and surgical techniques.

Episodes

What’s the story with mRNA vaccines?
What’s the story with mRNA vaccines? Jul 31, 2026 1415 What are mRNA vaccine, how do they work, and how might they be used for in the future? And why is there a gap between the evidence and some people’s perception of their safety and efficacy? Niall Boyce from The Lancet talks to Anna Blakney, biomedical engineer and one of the authors of new Review paper "Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective". Click here
What are cardiometabolic long-term conditions?
What are cardiometabolic long-term conditions? Jul 10, 2026 1156 What are cardiometabolic long-term conditions? To mark the publication of a new Lancet Series, editors Niall Boyce and Flávia Geraldes talk to Professor Kamlesh Khunti of the University of Leicester. They learn about a new way of conceptualising common medical conditions that has the potential to radically transform both health services and patient outcomes. Click here to read the full series: htt
Tania Nikolcheva, Gavin Giovannoni and Tharick Pascoal on the Special issue in Neurology
Tania Nikolcheva, Gavin Giovannoni and Tharick Pascoal on the Special issue in Neurology May 31, 2026 1954 In this episode of The Lancet In Conversation With, editors Niall Boyce and Bea Gómez Pérez-Nievas are joined by three leading researchers to discuss highlights from The Lancet's special issue on neurology. The conversation covers three landmark studies: the PADOVA trial of prasinezumab in early-stage Parkinson's disease, the ORATORIO-HAND study extending ocrelizumab treatment to wheelchair-using
Paul Spiegel: rethinking the humanitarian response to conflict and forced displacement
Paul Spiegel: rethinking the humanitarian response to conflict and forced displacement May 19, 2026 1911 Do we need to rethink our response to conflict and forced displacement? A new Lancet Commission radically rethinks policy, funding, and practical approaches to humanitarian crises. Chair Professor Paul Spiegel joins Niall Boyce from the Lancet to discuss the aims and recommendations of this Commission on one of the most pressing health issues of the 21st century. Click here to visit the commission
Can semaglutide be used to treat alcohol use disorder?
Can semaglutide be used to treat alcohol use disorder? May 2, 2026 1909 The Lancet’s Niall Boyce and Jonathan Pimm, and eBioMedicine’s Kalypso Karastergiou discuss an exciting new potential treatment for alcohol use disorder: semaglutide. As new research is published in The Lancet, they go behind the headlines with lead author Professor Anders Fink-Jensen to ask what the study showed, and what its implications are for the future of addiction medicine. Click here to re
Louise Chappell and Na’ama Carlin on Personal Cancer Stories
Louise Chappell and Na’ama Carlin on Personal Cancer Stories Feb 3, 2026 1839 The uniqueness of each patient is at the heart of this year's World Cancer Day. Each cancer patient has their own hopes, dreams and fears. In this Podcast you will hear from two cancer survivors about their unique experience with cancer and the importance of personalised cancer care not only on their bodies but also on their lives. Continue this conversation on social! Follow us today at... https:
Susannah Stanway on the London Global Cancer Week
Susannah Stanway on the London Global Cancer Week Dec 19, 2025 1444 In Conversation with The Lancet returns with Dr Susannah Stanway, honorary consultant medical oncologist at the Royal Marsden and honorary clinical senior lecturer in Education at the Institute of Cancer Research, reflecting on London Global Cancer Week 2025. This episode goes beyond event highlights to discuss the need for a global oncology agenda rooted in equity, evidence-based care, and value
Carlos Monteiro, Camila Corvalán, and Phil Baker on Ultra-Processed Foods and Human Health
Carlos Monteiro, Camila Corvalán, and Phil Baker on Ultra-Processed Foods and Human Health Dec 9, 2025 3677 Ultra-processed foods are on the rise. Despite the emphasis placed on individual responsibility, our deteriorating diets are primarily the result of the sophisticated political tactics of a powerful global ultra-processed food industry. Addressing this urgent threat demands a coordinated response from the global public health community. So argues a 3-paper Series published in The Lancet that exami
Presented at ASH: the EPCORE FL-1 study on epcoritamab in follicular lymphoma
Presented at ASH: the EPCORE FL-1 study on epcoritamab in follicular lymphoma Dec 7, 2025 783 Franck Morschhauser joins Ben Abbott of The Lancet to discuss the phase 3 EPCORE FL-1 study on epcoritamab, lenalidomide, and rituximab for relapsed or refractory follicular lymphoma, which is being presented at ASH 2025. Click here to read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02360-8/fulltext Continue this conversation on social! Follow us today at.
Presented at ESMO: the HARMONi-6 study on a bispecific antibody therapy for squamous NSCLC
Presented at ESMO: the HARMONi-6 study on a bispecific antibody therapy for squamous NSCLC Oct 19, 2025 1243 Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://faceb
Presented at ESMO: the POTOMAC study on immunotherapy in non-muscle-invasive bladder cancer
Presented at ESMO: the POTOMAC study on immunotherapy in non-muscle-invasive bladder cancer Oct 17, 2025 1329 Neal Shore joins Ben Abbott of The Lancet to discuss the phase 3 POTOMAC trial of durvalumab plus BCG in BCG-naïve, high-risk non-muscle-invasive bladder cancer, which is being presented at ESMO 2025. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedic
Stephen Chan on the Lancet Commission on addressing the global hepatocellular carcinoma burden
Stephen Chan on the Lancet Commission on addressing the global hepatocellular carcinoma burden Jul 28, 2025 1241 With the global burden of liver cancer growing, The Lancet has commissioned an international panel of experts to identify strategies to strengthen the prevention, surveillance, diagnosis, and treatment of liver cancer. Stephen Chan joins Ben Abbott of The Lancet to discuss the key messages of the Commission, which is published today on World Hepatitis Day. Read the full Commission: https://www.the

Recommended